Pfizer/Bristol finalize metabolics development deal
Executive Summary
Pfizer and Bristol-Myers Squibb finalize agreement to research, develop and commercialize DGAT-1 inhibitors. Companies announced deal to collaborate on the DGAT-1 discovery program, which includes advanced pre-clinical compounds with potential applications for treatment of metabolic disorders like obesity and diabetes, in April (1"The Pink Sheet" April 30, 2007, p. 4). Pfizer will be responsible for all research and early-stage development, and the companies will jointly conduct Phase III development and commercialization. The two firms also have a separate deal to develop and market the Factor Xa inhibitor apixaban. Initial filing for apixaban, for venous thromboembolism, is expected in the second half of 2009...